Gossamer Bio Publishes TORREY Phase 2 Results in Lancet Respiratory Medicine

Gossamer Bio, Inc., a biopharmaceutical firm dedicated to advancing pulmonary arterial hypertension (PAH) treatments, has reported the publication of their Phase 2 TORREY study in the Lancet Respiratory Medicine journal. The study, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial," showcases the positive outcomes of seralutinib, a drug developed by Gossamer Bio, in treating PAH.

The TORREY study was a multicenter, multinational effort that randomized 86 participants to receive seralutinib or a placebo via inhalation twice daily for 24 weeks. The research demonstrated a significant reduction in pulmonary vascular resistance (PVR) for those treated with seralutinib, along with improvements in right heart structure and function.

The success of the TORREY study has led to the initiation of the global Phase 3 PROSERA Study, which is currently underway to further evaluate seralutinib's efficacy in treating PAH patients classified as WHO Functional Class II and III. More information on the PROSERA study can be found on the clinical trials registry.

Faheem Hasnain, CEO, Co-founder, and Chairman of Gossamer Bio, highlighted the significance of the publication in addressing the medical needs of PAH patients and expressed optimism about seralutinib's potential to enhance patient lives.

Gossamer Bio is a clinical-stage company aiming to be a leader in the pulmonary hypertension field, focusing on the development and commercialization of seralutinib. The company's mission is to improve the quality of life for patients suffering from pulmonary hypertension.

The manuscript detailing the TORREY study's findings is accessible online and will also appear in a forthcoming print edition of the Lancet Respiratory Medicine journal.